VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
NCT01132859 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-04-14
Summary
Background:
\- The Vaccine Research Center (VRC) is dedicated to understanding immune responses associated with prevention and treatment of infectious diseases. To study these immune responses, researchers need to collect specimens and images from individuals who have recently had a vaccination or recovered from an infection. These specimens and images are used to study different diseases and immune responses, and can be used to investigate ways to prevent or treat different medical conditions.
Objectives:
\- To evaluate blood and other tissue samples for immune responses to vaccines and natural infections.
Eligibility:
\- Healthy volunteers at least 18 years of age who agree to donate specimens for research purposes.
Design:
* Participants will have clinical evaluations and will be asked to provide some of the following samples, depending on the research question being addressed. All procedures and sample donations are optional and voluntary:
* Blood samples through regular blood draws (for whole blood) and apheresis (to collect specific parts of the blood such as plasma or white blood cells)
* Urine, semen, saliva, or vaginal swab samples
* Tissue samples or biopsy specimens
* Undergo procedures such as bronchoscopy (lung and respiratory tract), gastrointestinal endoscopy (stomach and upper intestinal tract), or colonoscopy (lower intestinal tract) to obtain tissue samples
* Undergo imaging studies such as positron emission tomography (PET) or computed tomography (CT) scans
Duration of participation is variable depending on the research question but will usually last up to 1 year.
\- Participants will be compensated for participation.
Conditions
- Immunity, Mucosal
- Immune System Processes
- Blood Specimen Collection
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Lesia K Dropulic, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-05-18
Countries
- United States
Study Locations
More Related Trials
-
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
NCT04743388 ·Status: UNKNOWN
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Blood Sampling of Healthy Volunteers for Immunological Research
NCT03819829 ·Status: RECRUITING ·Phase: NA
-
Transcriptomics Signature of Anti Vaccinia Memory B Cells
NCT02556489 ·Status: UNKNOWN
-
Immune Response to the COVID-19 Vaccine
NCT04936997 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Human Immunome Program
NCT03118687 ·Status: COMPLETED
-
Immune Profiling for Cancer Immunotherapy Response
NCT06116032 ·Status: RECRUITING
-
Vaccine Response With NT-I7
NCT04054752 ·Status: WITHDRAWN ·Phase: PHASE1
-
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
NCT03207854 ·Status: RECRUITING
-
Dendritic Cell Based Therapy of Renal Cell Carcinoma
NCT00197860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539 ·Status: RECRUITING
-
Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults
NCT00346619 ·Status: COMPLETED ·Phase: PHASE1
-
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
NCT06300853 ·Status: RECRUITING ·Phase: NA
-
Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans
NCT04565067 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
NCT06935266 ·Status: COMPLETED ·Phase: PHASE1
-
Immunity to Infection in Healthy Participants and Participants With Cancer
NCT05787964 ·Status: ACTIVE_NOT_RECRUITING
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
NCT04871932 ·Status: RECRUITING
-
Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization
NCT01083745 ·Status: UNKNOWN
-
ImmuneRACE - Immune Response Action to COVID-19 Events
NCT04494893 ·Status: COMPLETED
-
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency
NCT06954441 ·Status: RECRUITING ·Phase: PHASE3
-
RNA-Loaded Dendritic Cell Cancer Vaccine
NCT00087984 ·Status: COMPLETED ·Phase: PHASE1/PHASE2